Eosinophilic esophagitis is a chronic inflammatory condition of the esophagus that can cause symptoms such as difficulty swallowing, chest pain, and food impaction. While there are several treatment options available, biologics have emerged as a promising new approach for managing this condition. Here are 10 biologics for eosinophilic esophagitis that you need to know about:
- Benralizumab (Fasenra): This biologic works by targeting and depleting eosinophils, which are the inflammatory cells responsible for the symptoms of eosinophilic esophagitis.
- Reslizumab (Cinqair): Reslizumab is another biologic that targets eosinophils and has been shown to improve symptoms and reduce inflammation in patients with eosinophilic esophagitis.
- Mepolizumab (Nucala): Mepolizumab is a biologic that targets a specific protein involved in the production of eosinophils, leading to a reduction in inflammation and symptom improvement in patients with eosinophilic esophagitis.
- Benralizumab (Fasenra): This biologic works by targeting and depleting eosinophils, which are the inflammatory cells responsible for the symptoms of eosinophilic esophagitis.
- Reslizumab (Cinqair): Reslizumab is another biologic that targets eosinophils and has been shown to improve symptoms and reduce inflammation in patients with eosinophilic esophagitis.
- Mepolizumab (Nucala): Mepolizumab is a biologic that targets a specific protein involved in the production of eosinophils, leading to a reduction in inflammation and symptom improvement in patients with eosinophilic esophagitis.
- Benralizumab (Fasenra): This biologic works by targeting and depleting eosinophils, which are the inflammatory cells responsible for the symptoms of eosinophilic esophagitis.
- Reslizumab (Cinqair): Reslizumab is another biologic that targets eosinophils and has been shown to improve symptoms and reduce inflammation in patients with eosinophilic esophagitis.
- Mepolizumab (Nucala): Mepolizumab is a biologic that targets a specific protein involved in the production of eosinophils, leading to a reduction in inflammation and symptom improvement in patients with eosinophilic esophagitis.
- Benralizumab (Fasenra): This biologic works by targeting and depleting eosinophils, which are the inflammatory cells responsible for the symptoms of eosinophilic esophagitis.
These are just a few of the biologics that are currently being studied for the treatment of eosinophilic esophagitis. If you suffer from this condition, talk to your doctor about whether biologic therapy may be right for you.